Iksuda is a biotechnology company that focuses on developing antibody-based therapies for the treatment of cancer. It provides PermaLink, conjugation chemistry for improved ADC stability, ultra-potent toxins for tumour killing, as well as antibodies targeted towards antigens associated with solid tumours.